Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study
<p>Abstract</p> <p>Background</p> <p>There is evidence of functional growth hormone (GH) deficiency, expressed by means of low insulin-like growth factor 1 (IGF-1) serum levels, in a subset of fibromyalgia patients. The efficacy of GH versus placebo has been previously...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-11-01
|
| Series: | BMC Musculoskeletal Disorders |
| Online Access: | http://www.biomedcentral.com/1471-2474/8/119 |
| _version_ | 1811321743754657792 |
|---|---|
| author | Güell Maria Riudavets Cristina Cuatrecasas Guillem Nadal Albert |
| author_facet | Güell Maria Riudavets Cristina Cuatrecasas Guillem Nadal Albert |
| author_sort | Güell Maria |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>There is evidence of functional growth hormone (GH) deficiency, expressed by means of low insulin-like growth factor 1 (IGF-1) serum levels, in a subset of fibromyalgia patients. The efficacy of GH versus placebo has been previously suggested in this population. We investigated the efficacy and safety of low dose GH as an adjunct to standard therapy in the treatment of severe, prolonged and well-treated fibromyalgia patients with low IGF-1 levels.</p> <p>Methods</p> <p>Twenty-four patients were enrolled in a randomized, open-label, best available care-controlled study. Patients were randomly assigned to receive either 0.0125 mg/kg/d of GH subcutaneously (titrated depending on IGF-1) added to standard therapy or standard therapy alone during one year. The number of tender points, the Fibromyalgia Impact Questionnaire (FIQ) and the EuroQol 5D (EQ-5D), including a Quality of Life visual analogic scale (EQ-VAS) were assessed at different time-points.</p> <p>Results</p> <p>At the end of the study, the GH group showed a 60% reduction in the mean number of tender points (pairs) compared to the control group (p < 0.05; 3.25 ± 0.8 <it>vs</it>. 8.25 ± 0.9). Similar improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001). There was a prompt response to GH administration, with most patients showing improvement within the first months in most of the outcomes. The concomitant administration of GH and standard therapy was well tolerated, and no patients discontinued the study due to adverse events.</p> <p>Conclusion</p> <p>The present findings indicate the advantage of adding a daily GH dose to the standard therapy in a subset of severe fibromyalgia patients with low IGF-1 serum levels.</p> <p>Trial Registration</p> <p>NCT00497562 (ClinicalTrials.gov).</p> |
| first_indexed | 2024-04-13T13:22:58Z |
| format | Article |
| id | doaj.art-935fb88caf0442e79b09be1a9d774ce6 |
| institution | Directory Open Access Journal |
| issn | 1471-2474 |
| language | English |
| last_indexed | 2024-04-13T13:22:58Z |
| publishDate | 2007-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Musculoskeletal Disorders |
| spelling | doaj.art-935fb88caf0442e79b09be1a9d774ce62022-12-22T02:45:15ZengBMCBMC Musculoskeletal Disorders1471-24742007-11-018111910.1186/1471-2474-8-119Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot studyGüell MariaRiudavets CristinaCuatrecasas GuillemNadal Albert<p>Abstract</p> <p>Background</p> <p>There is evidence of functional growth hormone (GH) deficiency, expressed by means of low insulin-like growth factor 1 (IGF-1) serum levels, in a subset of fibromyalgia patients. The efficacy of GH versus placebo has been previously suggested in this population. We investigated the efficacy and safety of low dose GH as an adjunct to standard therapy in the treatment of severe, prolonged and well-treated fibromyalgia patients with low IGF-1 levels.</p> <p>Methods</p> <p>Twenty-four patients were enrolled in a randomized, open-label, best available care-controlled study. Patients were randomly assigned to receive either 0.0125 mg/kg/d of GH subcutaneously (titrated depending on IGF-1) added to standard therapy or standard therapy alone during one year. The number of tender points, the Fibromyalgia Impact Questionnaire (FIQ) and the EuroQol 5D (EQ-5D), including a Quality of Life visual analogic scale (EQ-VAS) were assessed at different time-points.</p> <p>Results</p> <p>At the end of the study, the GH group showed a 60% reduction in the mean number of tender points (pairs) compared to the control group (p < 0.05; 3.25 ± 0.8 <it>vs</it>. 8.25 ± 0.9). Similar improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001). There was a prompt response to GH administration, with most patients showing improvement within the first months in most of the outcomes. The concomitant administration of GH and standard therapy was well tolerated, and no patients discontinued the study due to adverse events.</p> <p>Conclusion</p> <p>The present findings indicate the advantage of adding a daily GH dose to the standard therapy in a subset of severe fibromyalgia patients with low IGF-1 serum levels.</p> <p>Trial Registration</p> <p>NCT00497562 (ClinicalTrials.gov).</p>http://www.biomedcentral.com/1471-2474/8/119 |
| spellingShingle | Güell Maria Riudavets Cristina Cuatrecasas Guillem Nadal Albert Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study BMC Musculoskeletal Disorders |
| title | Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study |
| title_full | Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study |
| title_fullStr | Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study |
| title_full_unstemmed | Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study |
| title_short | Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study |
| title_sort | growth hormone as concomitant treatment in severe fibromyalgia associated with low igf 1 serum levels a pilot study |
| url | http://www.biomedcentral.com/1471-2474/8/119 |
| work_keys_str_mv | AT guellmaria growthhormoneasconcomitanttreatmentinseverefibromyalgiaassociatedwithlowigf1serumlevelsapilotstudy AT riudavetscristina growthhormoneasconcomitanttreatmentinseverefibromyalgiaassociatedwithlowigf1serumlevelsapilotstudy AT cuatrecasasguillem growthhormoneasconcomitanttreatmentinseverefibromyalgiaassociatedwithlowigf1serumlevelsapilotstudy AT nadalalbert growthhormoneasconcomitanttreatmentinseverefibromyalgiaassociatedwithlowigf1serumlevelsapilotstudy |